Overview

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Status:
Not yet recruiting

Trial end date:
2029-06-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas. Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.

Phase:

Phase 2

Details

Lead Sponsor:

Immune Oncology Research Institute

Collaborator:

Agenus Inc.